Guichard JB, Anselme F, Defaye P, et al. - Use of ramipril for renin-angiotensin-aldosterone system inhibition does not result in reduced atrial fibrillation (AF) occurrence in patients facing atrial flutter (AFL) ablation during the 1-year follow-up.

• In this prospective, multicenter, randomized, double-blind, double-dummy trial, a total of 198 patients hospitalized for AFL ablation were randomized to placebo or ramipril 5 mg/day.

• In the intention-to-treat population, there were 97 patients in the ramipril group and 101 in the placebo group.

• No difference in AF occurrence during the 1-year follow-up (primary endpoint) was found between the 2 groups.

• Similarly, there was no difference in secondary endpoints (including the occurrence of supraventricular arrhythmia, heart failure, stroke, and death) between the 2 groups.

• Also, safety outcome parameters did not differ between the 2 groups.